JP5623740B2 - 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 - Google Patents

遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 Download PDF

Info

Publication number
JP5623740B2
JP5623740B2 JP2009521759A JP2009521759A JP5623740B2 JP 5623740 B2 JP5623740 B2 JP 5623740B2 JP 2009521759 A JP2009521759 A JP 2009521759A JP 2009521759 A JP2009521759 A JP 2009521759A JP 5623740 B2 JP5623740 B2 JP 5623740B2
Authority
JP
Japan
Prior art keywords
serca2a
aav2
infusion
polynucleotide
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009521759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544698A5 (https=
JP2009544698A (ja
Inventor
クリスチーナ・マリア・ゼボ
Original Assignee
セラドン・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラドン・コーポレーション filed Critical セラドン・コーポレーション
Publication of JP2009544698A publication Critical patent/JP2009544698A/ja
Publication of JP2009544698A5 publication Critical patent/JP2009544698A5/ja
Application granted granted Critical
Publication of JP5623740B2 publication Critical patent/JP5623740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2009521759A 2006-07-25 2007-07-16 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 Active JP5623740B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83332406P 2006-07-25 2006-07-25
US60/833,324 2006-07-25
PCT/US2007/016129 WO2008013692A2 (en) 2006-07-25 2007-07-16 Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014156560A Division JP2014218509A (ja) 2006-07-25 2014-07-31 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Publications (3)

Publication Number Publication Date
JP2009544698A JP2009544698A (ja) 2009-12-17
JP2009544698A5 JP2009544698A5 (https=) 2010-09-02
JP5623740B2 true JP5623740B2 (ja) 2014-11-12

Family

ID=38581949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009521759A Active JP5623740B2 (ja) 2006-07-25 2007-07-16 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
JP2014156560A Pending JP2014218509A (ja) 2006-07-25 2014-07-31 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014156560A Pending JP2014218509A (ja) 2006-07-25 2014-07-31 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Country Status (13)

Country Link
US (2) US20080076730A1 (https=)
EP (2) EP2460879A1 (https=)
JP (2) JP5623740B2 (https=)
KR (1) KR20090035711A (https=)
CN (1) CN101495627A (https=)
AU (1) AU2007277392A1 (https=)
CA (1) CA2658628A1 (https=)
DK (1) DK2044199T3 (https=)
ES (1) ES2398593T3 (https=)
GB (1) GB2437893A (https=)
IL (1) IL196541A (https=)
PL (1) PL2044199T3 (https=)
WO (1) WO2008013692A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105135A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
PH12012501579A1 (en) * 2010-01-05 2012-10-22 Michael Aaron Vertical axis variable geometry wind energy collection system
US11583662B2 (en) 2016-04-18 2023-02-21 Sardocor Corp. Methods and compositions for consistent intracoronary administration of a biologic
KR20190139951A (ko) * 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) * 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US5773289A (en) * 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US20050095227A1 (en) * 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
JP2002502885A (ja) * 1998-02-11 2002-01-29 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA2373110A1 (en) * 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
WO2001096587A2 (en) * 2000-06-13 2001-12-20 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
WO2002019966A2 (en) * 2000-09-06 2002-03-14 Johns Hopkins University Cardiac arrhythmia treatment methods
ATE423574T1 (de) * 2000-09-11 2009-03-15 Univ California Dominant-negativer plb mutant zur behandlung der herzerkrankungen
MX359371B (es) * 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
JP2009513556A (ja) * 2003-07-17 2009-04-02 バイエリッシェ ユリウス−マクシミリアンズ−ウニヴァージタット ヴュルツブルグ 狭窄および再狭窄を阻害するための医薬品の製造におけるｆａｋ関連非キナーゼの使用
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
EP1691609A4 (en) * 2003-12-11 2006-11-29 Mirus Bio Corp RELEASE OF VIRUS VECTORS ANEXTRAVASAL PARENCHYM CELLS
US20060148742A1 (en) * 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CN101056539B (zh) * 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
WO2009105135A1 (en) * 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium

Also Published As

Publication number Publication date
EP2044199B1 (en) 2012-11-14
WO2008013692A2 (en) 2008-01-31
IL196541A0 (en) 2009-11-18
AU2007277392A1 (en) 2008-01-31
KR20090035711A (ko) 2009-04-10
PL2044199T3 (pl) 2013-04-30
ES2398593T3 (es) 2013-03-20
EP2044199A2 (en) 2009-04-08
GB0716413D0 (en) 2007-10-03
EP2460879A1 (en) 2012-06-06
JP2009544698A (ja) 2009-12-17
GB2437893A (en) 2007-11-07
JP2014218509A (ja) 2014-11-20
CA2658628A1 (en) 2008-01-31
US20080076730A1 (en) 2008-03-27
CN101495627A (zh) 2009-07-29
US20170252462A1 (en) 2017-09-07
IL196541A (en) 2012-12-31
DK2044199T3 (da) 2013-02-11
WO2008013692A3 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
EA001616B1 (ru) Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US20060148742A1 (en) Polynucleotide delivery to cardiac tissue
JP2004313198A (ja) 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入
CN116887868A (zh) 达农病的治疗
US8636998B2 (en) Method for enhanced uptake of viral vectors in the myocardium
CN105452458A (zh) 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EA005157B1 (ru) Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов
JP7450244B2 (ja) 虚血組織を治療するための方法
US8445454B2 (en) Use on minicircle vectors for cardiac gene therapy
WO2024233783A1 (en) Expression cassette coding for vascular endothelial growth factor
JP2024504085A (ja) 筋ジストロフィーを治療するための方法および組成物
Docherty Adenovirus Mediated Gene Transfer of Skeletal Troponin C to Myocardium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140925

R150 Certificate of patent or registration of utility model

Ref document number: 5623740

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250